• See Also
  1. Infant Respiratory Distress Syndrome
  • Indications
  1. Infant Respiratory Distress Syndrome
  • Mechanism
  1. Surfactant replacement decreases lung surface tension, allowing for greater alveoli opening
  • Medications
  1. Survanta (Beractant)
    1. Supplemented extract from calf lung
    2. Available in 25 mg/ml (vials contain 4 or 8 mls)
  2. Calfactant (Infasurf)
    1. Calf lung lavage extract
    2. Available in 35 mg/ml (vials contain 3 or 6 mls)
  3. Exosurf
    1. Synthetic surfactant analog
  • Dosing
  1. Surfactant delivery via Endotracheal Tube
  2. Dose 200 mg/kg for initial dose
  3. Followed by weaning Endotracheal Tube to Nasal CPAP
  • Adverse Effects
  1. Pulmonary Hemorrhage
  2. During instillation via Endotracheal Tube
    1. Oxygen Desaturation
    2. Bradycardia
  • Resources
  1. Calfactant (Infasurf)
    1. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=315c128a-272d-4c57-bfbe-1a8b3402af08&type=display
  2. Beractant (Survanta) Suspension
    1. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ef9e3a5-fc39-4ae1-0dad-6b47a1684635
  • References
  1. Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 90